Myles Brown

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States 
"Myles Brown"
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Cejas P, Xie Y, Font-Tello A, et al. (2021) Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nature Communications. 12: 5775
Wang X, Tokheim C, Gu SS, et al. (2021) In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell
Zeng Z, Wong CJ, Yang L, et al. (2021) TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response. Nucleic Acids Research
Tewari AK, Cheung ATM, Crowdis J, et al. (2021) Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. Cell Reports. 36: 109665
Liang J, Wang L, Poluben L, et al. (2021) Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells. Cancer Letters
Gu S, Lheureux S, Sayad A, et al. (2021) Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. Proceedings of the National Academy of Sciences of the United States of America. 118
Watt AC, Cejas P, DeCristo MJ, et al. (2021) CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nature Cancer. 2: 34-48
Wu Z, Zhou J, Zhang X, et al. (2021) Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. Nature Genetics
Baca SC, Takeda DY, Seo JH, et al. (2021) Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nature Communications. 12: 1979
Gu SS, Zhang W, Wang X, et al. (2021) Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. Cancer Discovery
See more...